TGTX Stock Analysis: TG Therapeutics | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 9.751m USD | 12M Return: 104.3% | US88322Q1085 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 111M
Qual. Beats: 0
Rev. Trend: 97.3%
Qual. Beats: 2
Warnings
Tailwinds
Seasonality 11.9 years of data, until 10/2026
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, ≥40 worth a closer look and ≥60 is strong.
TG Therapeutics, Inc. (NASDAQ: TGTX) is a commercial-stage biopharmaceutical company headquartered in Morrisville, North Carolina, that acquires, develops, and commercializes treatments for B-cell mediated diseases in the U.S. and international markets. The company markets BRIUMVI, an anti-CD20 monoclonal antibody approved for adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease.
Its clinical pipeline includes Ublituximab IV (an anti-CD20 mAb for relapsing MS), TG-1701 (an oral BTK inhibitor), and TG-1801 (a bispecific CD47/CD19 antibody), along with additional earlier-stage investigational programs. TG Therapeutics maintains license agreements with several partners, including LFB Biotechnologies, Ildong Pharmaceutical, and Jiangsu Hengrui Medicine, and has been listed on the Nasdaq since 1995.
Within the biotechnology sector, anti-CD20 monoclonal antibodies are a well-established class of therapies that target B-cells and are used across indications such as multiple sclerosis, lymphoma, and autoimmune diseases. BTK inhibitors represent a newer class of oral therapies with applications in both oncology and immune-mediated conditions, while CD47-targeted antibodies have drawn industry attention for their potential in immuno-oncology.
- BRIUMVI sales growth drives revenue as MS market share expands
- Competition intensifies from Ocrevus and Kesimpta in relapsing MS
- Pipeline catalysts from TG-1701 BTK inhibitor and TG-1801 bispecific programs
- Cash burn narrows as commercial-stage margins improve toward profitability
| Net Income: 106.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.05 > 0.02 and ΔFCF/TA 12.23 > 1.0 |
| NWC/Revenue: 101.5% < 20% (prev 83.28%; Δ 18.19% < -1%) |
| CFO/TA 0.05 > 3% & CFO 86.3m > Net Income 106.1m |
| Net Debt (258.4m) to EBITDA (191.3m): 1.35 < 3 |
| Current Ratio: 4.50 > 1.5 & < 3 |
| Outstanding Shares: last quarter (155.9m) vs 12m ago -3.15% < -2% |
| Gross Margin: 82.74% > 18% (prev 85.33%; Δ -2.59% > 0.5%) |
| Asset Turnover: 68.60% > 50% (prev 51.89%; Δ 16.71% > 0%) |
| Interest Coverage Ratio: 4.10 > 6 (EBIT TTM 191.0m / Interest Expense TTM 46.6m) |
| A: 0.57 (Total Current Assets 1.17b - Total Current Liabilities 260.5m) / Total Assets 1.59b |
| B: -0.63 (Retained Earnings -999.0m / Total Assets 1.59b) |
| C: 0.15 (EBIT TTM 191.0m / Avg Total Assets 1.31b) |
| D: 0.56 (Book Value of Equity 572.1m / Total Liabilities 1.02b) |
| Altman-Z'' = 3.28 = A |
| DSRI: 0.93 (Receivables 416.8m/265.4m, Revenue 897.8m/531.9m) |
| GMI: 1.03 (GM 85.33% / 82.74%) |
| AQI: 0.64 (AQ_t 0.26 / AQ_t-1 0.41) |
| SGI: 1.69 (Revenue 897.8m / 531.9m) |
| TATA: 0.01 (NI 106.1m - CFO 86.3m) / TA 1.59b) |
| Beneish M = -2.78 (Cap -4..+1) = A |
As of November 18, 2026, the stock is trading at USD 62.71 with a total of 1,714,250 shares traded. Over the past week, the price has changed by -2.41%, over one month by +17.65%, over three months by +27.25% and over the past year by +104.33%.
Current recommended Stop Loss: 55.50 (which is 11.5% or 2.3 ATR below the current price).
TG Therapeutics has received a consensus analysts rating of 4.43. Therefore, it is recommended to buy TGTX.
- StrongBuy: 5
- Buy: 1
- Hold: 0
- Sell: 1
- StrongSell: 0
| Analysts Target Price | 69.4 | 10.7% |
P/E Trailing = 96.2836
P/E Forward = 29.8507
P/S = 10.8609
P/B = 17.0426
P/EG = 1.6144
Revenue TTM = 897.8m USD
EBIT TTM = 191.0m USD
EBITDA TTM = 191.3m USD
Long Term Debt = 745.6m USD (from longTermDebt, last quarter)
Short Term Debt = 1.84m USD (from shortTermDebt, last quarter)
Debt = 763.1m USD (from shortLongTermDebtTotal, last quarter) + Leases 8.74m
Net Debt = 258.4m USD (calculated: Debt 763.1m - CCE 504.7m)
Enterprise Value = 10.0b USD (9.75b + Debt 763.1m - CCE 504.7m)
Interest Coverage Ratio = 4.10 (Ebit TTM 191.0m / Interest Expense TTM 46.6m)
EV/FCF = 117.0x (Enterprise Value 10.0b / FCF TTM 85.6m)
FCF Yield = 0.85% (FCF TTM 85.6m / Enterprise Value 10.0b)
FCF Margin = 9.53% (FCF TTM 85.6m / Revenue TTM 897.8m)
Net Margin = 11.81% (Net Income TTM 106.1m / Revenue TTM 897.8m)
Gross Margin = 82.74% ((Revenue TTM 897.8m - Cost of Revenue TTM 154.9m) / Revenue TTM)
Gross Margin QoQ = 83.81% (prev 82.86%)
Tobins Q-Ratio = 6.29 (Enterprise Value 10.0b / Total Assets 1.59b)
Interest Expense / Debt = 6.11% (Interest Expense 46.6m / Debt 763.1m)
Taxrate = 29.08% (43.5m / 149.6m)
NOPAT = 135.5m (EBIT 191.0m * (1 - 29.08%))
Current Ratio = 4.50 (Total Current Assets 1.17b / Total Current Liabilities 260.5m)
Debt / Equity = 1.33 (Debt 763.1m / totalStockholderEquity, last quarter 572.1m)
Debt / EBITDA = 1.35 (Net Debt 258.4m / EBITDA 191.3m)
Debt / FCF = 3.02 (Net Debt 258.4m / FCF TTM 85.6m)
Total Stockholder Equity = 601.8m (last 4 quarters mean from totalStockholderEquity)
RoA = 8.10% (Net Income 106.1m / Total Assets 1.59b)
RoE = 17.62% (Net Income TTM 106.1m / Total Stockholder Equity 601.8m)
RoCE = 14.18% (EBIT 191.0m / Capital Employed (Equity 601.8m + L.T.Debt 745.6m))
RoIC = 10.51% (NOPAT 135.5m / Invested Capital 1.29b)
WACC = 5.85% (E(9.75b)/V(10.5b) * Re(5.97%) + D(763.1m)/V(10.5b) * Rd(6.11%) * (1-Tc(0.29)))
Discount Rate = 5.97% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -59.01 | Cagr: -0.98%
[DCF] Terminal Value 75.44% ; FCFF base≈85.6m ; Y1≈85.9m ; Y5≈91.0m
[DCF] Fair Price = 7.66 (EV 1.42b - Net Debt 258.4m = Equity 1.16b / Shares 151.1m; r=8.35% [WACC [floored]]; 5y FCF grow 0.0% → 2.50% )
EPS Correlation: N/A | EPS CAGR: N/A | SUE: 0.55 | # QB: 0
Revenue Correlation: 97.32 | Revenue CAGR: 62.47% | SUE: 2.73 | # QB: 2
EPS current Quarter (2027-03-31): EPS=0.60 | Chg30d=+33.33% | Revisions=-25% | Analysts=1
EPS current Year (2026-12-31): EPS=0.97 | Chg30d=+2.11% | Revisions=-50% | GrowthEPS=-65.0% | GrowthRev=+62.2%
EPS next Year (2027-12-31): EPS=2.55 | Chg30d=-5.71% | Revisions=+0% | GrowthEPS=+163.2% | GrowthRev=+34.5%
[Analyst] Revisions Ratio: -36% (up=2, down=6)